Skip to main content
Premium Trial:

Request an Annual Quote

CambridgeSoft, Goldman Sachs, University of Florida, Geospiza, Wellcome Trust, European Bioinformatics Institute, Galapagos, Health Discovery Corporation, DCL Medical Laboratories

Premium
CambridgeSoft Raises $21M
 
Life science informatics developer CambridgeSoft said this week that it has completed a $21 million private equity investment by Goldman Sachs.
 
In connection with the offering, Raheel Zia, a vice president at Goldman Sachs Principal Investment Area, will join CambridgeSoft's board of directors.
 
In addition, CambridgeSoft said that it has hired Michael Stapleton as vice president of corporate development (see People in the News, this issue).
 

 
Florida Center to Use Geospiza’s Finch for Next-Gen Sequencing
 
The University of Florida has purchased Geospiza’s lab-management software for its genomics sequencing lab, the company said this week.
 
Under the agreement, the Interdisciplinary Center for Biotechnology Research's Next Generation DNA Sequencing Laboratory will use Geospiza’s FinchLab platform, which is used for managing labs with multiple genetic analysis technologies, including capillary electrophoresis and next-generation sequencing tools from Applied Biosystems and Roche/454.
 
Bill Farmerie, associate director at ICBR, said that his group has been using Geospiza’s software to manage data from its capillary electrophoresis sequencers for eight years and that the software has “allowed our bioinformatics group to focus foremost on high-level data analysis for our user community rather than divert time and energy to solving routine data management tasks."
 
Financial terms of the agreement were not released.
 

 
Wellcome Trust Provides $9.4M to Publicly Release Galapagos’ Data Via EBI
 
The UK’s Wellcome Trust, the European Bioinformatics Institute, and Belgian biotech firm Galapagos have signed an agreement that will open up the rights to databases held by Galapagos division BioFocus DPI for use by public research communities.
 
Under the terms of the agreement, EBI will use a Wellcome Trust grant of £4.7 million ($9.4 million) to support the transfer of a collection of information on drug properties and a set of Galapagos’ drug-like small molecules to the institute. EBI will incorporate the data into its collection of open-access resources for use in biomedical research.
 
Galapagos will receive £1.4 million for the data, which it previously offered for license through its BioFocus DPI service division.
 
The Galapagos databases covered under the agreement are DrugStore, StARLITe, Strudle, Kinase SARfari, and GPCR SARfari.
 
The agreement does not include the StarDrop software platform, which BioFocus DPI will continue to offer.
 
"The scientific community worldwide will greatly benefit from the access to these data for aiding predictive drug discovery," Galapagos CEO Onno van de Stolpe said in a statement.
 

 
Health Discovery, DCL Ink Cancer Dx Collaboration
 
Health Discovery Corporation said this week that it has partnered with DCL Medical Laboratories to develop and commercialize diagnostic tests for ovarian, cervical, and endometrial cancers based on support vector machine technology.
 
Under the agreement, HDC will own the developed intellectual property and DCL will have a sole-use license for applications and new mathematical tools that are developed over the course of the collaboration.
 
HDC is focused on SVM-based molecular diagnostic tests in genomics, proteomics, digital image analysis, and radiology.
 
Financial terms of the agreement were not released.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.